Percutaneous Techniques, Limitations and Challenges for the Failed Surgical Mitral Intervention.

Area of Science:

• Cardiology
• Interventional Cardiology
• Medical Devices

Background:

• Percutaneous therapies are transforming valvular heart disease treatment, expanding beyond transcatheter aortic valve replacement to address mitral valve pathology.
• Surgical mitral valve repair is the gold standard, but bioprosthetic valve use is increasing despite limited lifespan and reoperation risks.
• Less invasive techniques are appealing for aging populations with comorbidities, especially given the risks associated with reoperation.

Purpose of the Study:

• To review the current landscape of percutaneous mitral valve interventions, focusing on transcatheter mitral valve-in-valve (TMIVV) replacement.
• To highlight the benefits and challenges of TMIVV for failed bioprosthetic valves in high-risk surgical patients.
• To emphasize the importance of understanding and mitigating procedural complications for improved patient outcomes.

Main Methods:

• Review of current literature and clinical data on transcatheter mitral valve interventions.
• Analysis of outcomes and complications associated with transcatheter mitral valve-in-valve replacement.
• Discussion of procedural challenges, mitigation strategies, and therapeutic options.

Main Results:

• Transcatheter aortic valve replacement (TAVR) valves used in failed surgical valves show better short-term mortality than open reoperation.
• The US Food and Drug Administration approved transcatheter mitral valve-in-valve replacement for high-risk patients with failed bioprosthetic valves.
• TMIVV is associated with procedural challenges such as malpositioning, embolization, paravalvular leak, and outflow tract obstruction.

Conclusions:

• Transcatheter mitral valve-in-valve replacement is a viable, less invasive option for select high-risk patients with degenerated bioprosthetic mitral valves.
• Awareness of potential complications and implementation of mitigation strategies are essential for successful TMIVV procedures.
• Continued research and device development are needed to further optimize percutaneous approaches for mitral valve disease.